🇺🇸 Veqtio · US Equity Deep Dive
TGTX: TG Therapeutics, Inc. $30.07
52-wk High $46.48
📌 Investment Snapshot
- 💰 Price & Valuation: TGTX trades at a compelling 10.9x P/E (TTM), significantly below the S&P 500 average.
- 📈 Latest Quarter: Q4 FY25 revenue hit $193M, marking a robust +78.0% YoY growth.
- 🔑 Key Catalyst: Strong adoption of Briumvi for Multiple Sclerosis is driving revenue growth and accelerating the path to profitability.
- 🎯 Consensus: Wall Street maintains a BUY rating with a mean target of $44, implying +46.3% upside.
| 📍 Entry Zone | $29.50 or below | 🛑 Stop-Loss | $25.00 |
| 📋 Adjust If | Q1 FY26 revenue growth falls below +50% YoY. | ||
The Investment Case — Why Now?
TG Therapeutics is at a pivotal moment, driven by the accelerating adoption of its flagship drug, Briumvi, for multiple sclerosis. The latest Q4 FY25 earnings report showcased a remarkable +78.0% year-over-year revenue growth to $193M, far exceeding expectations and demonstrating strong market penetration. This rapid commercial success positions TGTX as a compelling growth story in the biotechnology sector, especially with its current 10.9x P/E offering a discount compared to many high-growth peers.
However, investors must weigh this growth against a significant bearish sentiment reflected in the 22.50% short interest. This high short positioning could amplify volatility, creating downside pressure if future growth metrics disappoint or if broader biotech sentiment sours. While it also presents a potential short squeeze opportunity, it remains the primary risk to monitor closely.
Company Overview
| Label | Value |
|---|---|
| Company | TG Therapeutics, Inc. |
| Ticker / Exchange | TGTX / NASDAQ |
| Sector / Industry | Healthcare / Biotechnology |
| CEO | Michael S. Weiss |
| Founded / HQ | 1993 / New York, NY |
Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| TGTX | (This stock) | 10.9x |
| S&P 500 Avg | S&P 500 Avg | 21.0x |
| UNH | UnitedHealth Group Incorporate | 20.8x |
| JNJ | Johnson & Johnson | 21.4x |
| LLY | Eli Lilly and Company | 39.5x |
| PFE | Pfizer, Inc. | 19.8x |
Price Action & Technicals
$30.07
+1.8%
+0.5%
-35.3%
Neutral
TGTX is currently trading at $30.07, positioned below its 200-day SMA of $32.33 but above its 50-day SMA of $29.56, suggesting a potential support level. The 14-day RSI at 53.2 indicates neutral to slightly bullish momentum, while MACD shows a neutral signal with a positive crossover. Furthermore, a volume ratio of 2.09x suggests significant trading activity, potentially indicating increased investor interest.
Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q4 FY25 | $193M | N/A | +78.0% |
| Q3 FY25 | $162M | $2.43 | +92.8% |
| Q2 FY25 | $141M | $0.17 | +92.1% |
| Q1 FY25 | $121M | $0.03 | +90.4% |
Growth Drivers — What Moves the Stock
- Briumvi (Ublituximab) Adoption (🟢): The primary growth engine for TGTX is the strong and accelerating uptake of Briumvi for Multiple Sclerosis. Q4 FY25 revenue surged +78.0% YoY, demonstrating significant market penetration and physician confidence. Continued market expansion and potential label extensions could sustain this impressive growth trajectory.
- Pipeline Expansion (🟡): While Briumvi dominates current revenue, TG Therapeutics maintains an active pipeline. Positive developments or successful clinical trials for other candidates could diversify future revenue streams and provide additional upside, though their impact is not yet fully priced into the current valuation.
Smart Money & Institutional Positioning
Institutional Holdings (13F Filings)
| Institution | Shares (K) |
|---|---|
| Blackrock Inc. | 21,848K |
| Vanguard Group Inc | 15,841K |
| State Street Corporation | 8,479K |
| ClearBridge Investments, | 3,448K |
| Geode Capital Management | 3,403K |
Holdings reflect most recent 13F (45-day lag). QoQ change not available.
Short Interest
| Metric | Value |
|---|---|
| Short % of Float | 22.50% |
| Days to Cover | 17.0 |
This high short interest suggests a significant bearish bet against TGTX, but also presents a potential short squeeze catalyst if positive news emerges.
Key Risk Factors — Risk Matrix
Clinical Trial Setbacks
Delays or negative outcomes in ongoing or future clinical trials for pipeline candidates could severely impact future revenue streams and investor confidence.
~$10B impact
Intense Competition
The biotechnology sector is highly competitive, especially in MS. New entrants or superior therapies from rivals could erode Briumvi’s market share.
~$7B impact
Regulatory Hurdles
Regulatory approvals are critical. Unexpected delays or stricter requirements from the FDA could hinder product launches or market access.
~$5B impact
Market Sentiment & Biotech Volatility
Biotechnology stocks are often volatile and sensitive to broader market sentiment, interest rate changes, and sector-specific news, which could impact TGTX’s valuation.
~$8B impact
Guidance & Wall Street View
Recent Analyst Actions
| Firm | Rating | Price Target | Date | Action |
|---|---|---|---|---|
| JP Morgan | Overweight | $46.00 | 2026-02-02 | Maintain |
| Goldman Sachs | Neutral | $39.00 | 2026-01-15 | Maintain |
Consensus Price Targets
| High Target | Mean Target | Low Target | Total Analysts | Consensus Rating |
|---|---|---|---|---|
| $60 | $44 | $15 | 7 | BUY |
The consensus BUY rating from 7 analysts, with a mean target of $44, implies a substantial +46.3% upside from the current price. The wide range from $60 (High) to $15 (Low) indicates varying levels of conviction, reflecting both the significant growth potential and inherent risks in the biotechnology sector.
Bull vs Bear — Probability-Weighted Scenarios
Bull Case
- Briumvi’s market penetration exceeds expectations, capturing a larger share of the MS market faster than anticipated, leading to sustained revenue beats.
- The company’s pipeline yields positive clinical trial results, opening new revenue streams and diversifying its product portfolio.
Implied Price Target: $55
Base Case
TGTX continues its strong Briumvi growth trajectory, meeting analyst expectations for revenue and gradually improving profitability. The stock trades closer to its mean analyst target of $44, reflecting its current growth and valuation.
Bear Case
- Increased competition or unexpected safety concerns for Briumvi lead to slower adoption rates and missed revenue targets.
- Clinical trial failures or regulatory setbacks for pipeline assets diminish future growth prospects, leading to a re-rating of the stock.
Implied Downside Target: $20
Disclaimer & Hashtags
This Veqtio analysis is for informational and educational purposes only and should not be considered investment advice. All investment decisions should be made with due diligence and consultation with a qualified financial professional. Past performance is not indicative of future results.
All active positions and their real-time performance are tracked on our Investment Log.
#TGTX #TGTherapeutics #USStocks #StockAnalysis #Veqtio #Biotechnology #Healthcare #Briumvi